Saturday 17 October 2026
Export COCH’s income statement to Excel — free account
Envoy Medical, Inc.
COCH Healthcare Medical Devices
Envoy Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $241,000.00, up 7.11% from fiscal 2024. In the quarter to June 2026, revenue fell 34.6%, EPS grew 78.1% and free cash flow fell 22.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.67
0.03
+4.69%
Follow COCH
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
397.06 | 197.38 | 63.70 | 81.95 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(15.06) | (7.62) | (2.70) | (3.94) | |
P/B ratio |
24.88 | 4.55 | 0.00 | 0.00 | |
Price to Tangible BV |
24.88 | 4.55 | 0.00 | 0.00 | |
EV/Sales |
449.92 | 220.33 | 175.25 | 212.07 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.33) | (2.51) | (2.32) | (2.51) | |
EV/FCF |
(4.29) | (2.49) | (2.30) | (2.58) | |
Quick Ratio |
1.56 | 2.07 | 0.33 | 0.40 | |
Current Ratio |
1.73 | 2.27 | 0.54 | 0.64 | |
Net Debt/EBITDA |
3.74 | 4.46 | 0.62 | 0.66 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.02 | 0.02 | |
Operating CF/Net income |
0.75 | 1.06 | 0.73 | 0.56 | |
Capex/Depreciation |
(0.02) | 0.00 | (0.56) | 0.00 | |
Interest Coverage |
— | — | — | (12.12) | |
Research and Development Expense of Revenue |
6,141.18% | 9,338.46% | 6,070.67% | 6,428.57% | |
Selling, General and Administrative Expense of Revenue |
4,333.33% | 5,238.46% | 2,261.33% | 6,778.57% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
482.35% | 725.64% | 153.33% | 771.43% | |
Graham Net Nets |
0.02 | 0.17 | (0.94) | (0.59) | |
Graham Number |
0.00 | 0.00 | 3.79 | 3.34 | |
Earnings Yield |
(96.20%) | (150.75%) | (184.85%) | (180.77%) | |
Free Cash Flow Yield |
(26.42%) | (44.85%) | (119.73%) | (100.21%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.05) | (0.09) | (0.24) | (0.20) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.05) | (0.09) | (0.25) | (0.20) | |
Cash per Share |
0.19 | 0.37 | 0.16 | 0.16 | |
Shareholders Equity per Share |
0.03 | 0.15 | (0.52) | (0.35) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.03 | 0.15 | (0.52) | (0.35) | |
Free Cash Flow |
(5.46) | (6.06) | (5.86) | (4.33) | |
Working Capital |
9.28 | 15.47 | (5.28) | (3.23) | |
Capital Expenditures |
(0.01) | — | (0.17) | 0.00 | |
Net Current Asset Value |
1.27 | 8.02 | (14.44) | (10.08) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.12 | 0.00 | 2.29 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.06 | 0.06 | 0.44 | 0.14 | |
Average Payables |
1.83 | 1.68 | 2.29 | 2.22 | |
Average Inventory |
1.58 | 1.57 | 1.63 | 1.64 | |
Average Assets |
16.92 | 20.10 | 10.05 | 8.79 | |
Average Common Equity |
(13.28) | (7.03) | (15.50) | (13.09) |
Columns are period end dates